Shield Therapeutics plc (STX) - Total Liabilities

Latest as of June 2025: GBX76.96 Million GBX ≈ $9.36K USD

Based on the latest financial reports, Shield Therapeutics plc (STX) has total liabilities worth GBX76.96 Million GBX (≈ $9.36K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore STX cash flow metrics to assess how effectively this company generates cash.

Shield Therapeutics plc - Total Liabilities Trend (2013–2024)

This chart illustrates how Shield Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. Check STX asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Shield Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Shield Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
Inspecs Group plc LSE:SPEC	UK	GBX114.73 Million
Trifast plc LSE:TRI	UK	GBX109.33 Million
Value & Income Trust LSE:VIP	UK	GBX51.79 Million
Thiensurat Public Company Limited BK:TSR	Thailand	฿1.95 Billion
Protagenic Therapeutics NASDAQ:PTIX	USA	$6.82 Million
BEACN Wizardry & Magic Inc V:BECN	Canada	CA$1.67 Million
Total Helium Ltd V:TOH	Canada	CA$2.67 Million
AfriTin Mining Ltd LSE:ATM	UK	GBX43.56 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Shield Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see STX market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.83	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-5.18	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shield Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shield Therapeutics plc (2013–2024)

The table below shows the annual total liabilities of Shield Therapeutics plc from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	GBX46.95 Million ≈ $5.71K	+77.25%
2023-12-31	GBX26.49 Million ≈ $3.22K	+59.11%
2022-12-31	GBX16.65 Million ≈ $2.03K	+392.51%
2021-12-31	GBX3.38 Million ≈ $411.25	+50.09%
2020-12-31	GBX2.25 Million ≈ $274.00	-46.05%
2019-12-31	GBX4.17 Million ≈ $507.86	+41.44%
2018-12-31	GBX2.95 Million ≈ $359.05	-21.58%
2017-12-31	GBX3.76 Million ≈ $457.85	-5.64%
2016-12-31	GBX3.99 Million ≈ $485.22	-81.45%
2015-12-31	GBX21.50 Million ≈ $2.62K	+11.48%
2014-12-31	GBX19.29 Million ≈ $2.35K	+139.66%
2013-12-31	GBX8.05 Million ≈ $979.21	--

About Shield Therapeutics plc

LSE:STX UK Drug Manufacturers - Specialty & Generic

Market Cap

$1.03 Million

GBX8.44 Billion GBX

Market Cap Rank

#30185 Global

#795 in UK

Share Price

GBX7.90

Change (1 day)

-9.71%

52-Week Range

GBX2.35 - GBX12.20

All Time High

GBX185.02